Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 7/20 | 0.69 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.49 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.49 |
| ▸ | CTSV | O60911 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9895242 | 0.91 | HIF1A (0.58) | HIF1AMAOBSIRT2 | |
| SCHEMBL9894619 | 0.91 | HIF1A (0.58) | HIF1AMAOB | |
| SCHEMBL9895099 | 0.91 | HIF1A (0.66) | HIF1AMAOBSPHK2SPHK1CTSV | |
| SCHEMBL9895094 | 0.91 | HIF1A (0.66) | HIF1AMAOBSPHK2SPHK1CTSV | |
| SCHEMBL9895092 | 0.91 | HIF1A (0.66) | HIF1AMAOBSPHK2SPHK1CTSV | |
| SCHEMBL9894315 | 0.91 | HIF1A (0.57) | HIF1AMAOBMRGPRX4 | |
| SCHEMBL9254199 | 0.89 | HIF1A (0.52) | HIF1AKDM4EALDH1A1 | |
| SCHEMBL9894779 | 0.88 | HIF1A (0.54) | HIF1AKDM4EALDH1A1BCHE | |
| SCHEMBL9894890 | 0.88 | HIF1A (0.67) | HIF1ASPHK2SPHK1 | |
| SCHEMBL9894943 | 0.87 | HIF1A (0.53) | HIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772290-B2 | Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same | Oscotech Inc. (KR) | 2014-07-08 | — | — | US | claimed |
| EP-2565180-A2 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Oscotec Inc. (KR) | 2013-03-06 | — | — | EP | claimed |
| US-20120149707-A1 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | OSCOTEC INC. (KR) | 2012-06-14 | — | — | US | claimed |
| US-8772290-B2 | Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same | Oscotech Inc. (KR) | 2014-07-08 | — | — | US | disclosed |
| EP-2565180-A2 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Oscotec Inc. (KR) | 2013-03-06 | — | — | EP | disclosed |
| US-20120149707-A1 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | OSCOTEC INC. (KR) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149707-A1 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | HIF1A, HIF1AN, EGLN3 | HIF1A 1/4885MAOB 2441/4885SPHK2 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.